<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2124d0de-8f96-6f0d-6c42-7296def2661f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information
needed to use PROHANCE safely and effectively. See full prescribing
information for PROHANCE.<br/>
      <br/>PROHANCE (gadoteridol
injection) single dose, for intravenous use<br/>Initial U.S.
Approval: 1992</title>
   <effectiveTime value="20250314"/>
   <setId root="778aee03-7d4c-481a-be8a-a75db0702f5a"/>
   <versionNumber value="24"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="849234661" root="1.3.6.1.4.1.519.1"/>
            <name>BRACCO DIAGNOSTICS INC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="849234661" root="1.3.6.1.4.1.519.1"/>
                  <name>BRACCO DIAGNOSTICS INC</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="434384007" root="1.3.6.1.4.1.519.1"/>
                        <name>BRACCO IMAGING SPA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-1111" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="342104149" root="1.3.6.1.4.1.519.1"/>
                        <name>BIPSO GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-1111" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-1111" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="314929072" root="1.3.6.1.4.1.519.1"/>
                        <name>Labor LS SE &amp; Co. KG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-1111" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="318354230" root="1.3.6.1.4.1.519.1"/>
                        <name>BioChem Labor  für biologishe und chemische</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-1111" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="434384008" root="1.3.6.1.4.1.519.1"/>
                        <name>Bracco Imaging SPA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-1111" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="db3c9ced-40d3-aebe-55c6-631b433a8b4c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240124"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0270-1111" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ProHance</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>gadoteridol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="279.3" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0199MV609F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>gadoteridol</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0199MV609F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>gadoteridol</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value=".23" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RPH56VWA1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>calteridol calcium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1.21" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="023C2WHX2V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>tromethamine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-1111-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19921116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-1111-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19921116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-1111-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19921116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-1111-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19921116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020131" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19921116"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="bb12441a-3f79-0377-d1de-f312b6597727"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC
FIBROSIS</title>
               <text>
                  <paragraph ID="p1078833641705970553">
                     <content styleCode="bold">
                        <content styleCode="underline">Risk Associated with Intrathecal Use</content>
                     </content>
                     <br/>
                     <content styleCode="bold">Intrathecal administration of gadolinium-based
contrast agents (GBCAs) can cause serious adverse reactions including
death, coma, encephalopathy, and seizures. ProHance is not approved
for intrathecal use <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph ID="p14872113641705970596">
                     <content styleCode="bold">
                        <content styleCode="underline">Nephrogenic Systemic Fibrosis</content>
                     </content>
                     <br/>
                     <content styleCode="bold">GBCAs increase the risk for nephrogenic
systemic fibrosis (NSF) among patients with impaired elimination of
the drugs. Avoid use of ProHance in these patients unless the diagnostic
information is essential and not available with non- contrasted MRI
or other modalities. NSF may result in fatal or debilitating systemic
fibrosis affecting the skin, muscle and internal organs.</content>
                  </paragraph>
                  <paragraph ID="p14882133641705970692">
                     <content styleCode="bold">The risk for NSF appears
highest among patients with:</content>
                  </paragraph>
                  <list listType="unordered" ID="l26133641705970734" styleCode="Circle">
                     <item>
                        <content styleCode="bold">chronic, severe kidney disease (GFR less than 30 mL/min/1.73m<sup>2</sup>), or</content>
                     </item>
                     <item>
                        <content styleCode="bold">acute kidney injury</content>
                     </item>
                  </list>
                  <paragraph ID="p10010123641705970876">
                     <content styleCode="bold">Screen patients
for acute kidney injury and other conditions that may reduce renal
function. For patients at risk for chronically reduced renal function
(e.g. age greater than 60 years, hypertension or diabetes), estimate
the glomerular filtration rate (GFR) through laboratory testing.</content>
                  </paragraph>
                  <paragraph ID="p999843641705971625">
                     <content styleCode="bold">For patients
at highest risk for NSF, do not exceed the recommended ProHance dose
and allow a sufficient period of time for elimination of the drug
from the body prior to re-administration <content styleCode="italics">[see Warnings and
Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p9216316261611115640">
                           <content styleCode="bold">WARNING: RISK ASSOCIATED
WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS</content>
                        </paragraph>
                        <paragraph ID="p9241716261611115669">
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing
information for complete boxed warning</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="l52233641705969992" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Intrathecal administration of gadolinium based contrast
agents (GBCAs) can cause serious adverse reactions including death,
coma, encephalopathy, and seizures. ProHance is not approved for intrathecal
use. (<linkHtml href="#Section_5.1">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">GBCAs increase the risk for nephrogenic systemic fibrosis
(NSF) among patients with impaired elimination of the drugs. Avoid
use of ProHance in these patients unless the diagnostic information
is essential and not available with non-contrasted MRI or other modalities.
NSF may result in fatal or debilitating systemic fibrosis affecting
the skin, muscle and internal organs. The risk for NSF appears highest
among patients with:</content>
                              <list listType="unordered" ID="l975523641705970155" styleCode="Circle">
                                 <item>
                                    <content styleCode="bold">chronic, severe kidney disease (GFR less than  30
mL/min/1.73m<sup>2</sup>), or</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">acute kidney injury</content>
                                 </item>
                              </list>
                              <content styleCode="bold">Screen patients for acute kidney injury and other conditions
that may reduce renal function. For patients at risk for chronically
reduced renal function (e.g. age greater than 60 years, hypertension
or diabetes), estimate the glomerular filtration rate (GFR) through
laboratory testing (<linkHtml href="#Section_5.2">5.2</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="af325d3c-9c85-0b07-4f30-9b2bce3369ff"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ProHanceMultipackIsAGadolinium-base-83010B1A">ProHance
is a gadolinium-based contrast agent indicated for magnetic resonance
imaging (MRI) to visualize:</paragraph>
                        <list listType="unordered" ID="LesionsWithDisruptedBloodBrainBarri-83011076" styleCode="Disc">
                           <item>lesions with disrupted blood brain barrier and/or abnormal
vascularity in the brain (intracranial lesions), spine and associated
tissues in adults and pediatric patients, including term neonates (<linkHtml href="#Section_1.1">1.1</linkHtml>)</item>
                           <item>lesions in the head and neck in adults (<linkHtml href="#Section_1.2">1.2</linkHtml>)</item>
                        </list>
                        <paragraph ID="p146382301741952507">
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="4c39da50-e53d-42fd-a1fc-e1e3b61a70cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 MRI of the Central
Nervous System (CNS)</title>
                     <text>
                        <paragraph ID="ProHanceIsIndicatedForMagneticReson-83011A96">ProHance is indicated
for magnetic resonance imaging (MRI) in adults and pediatric patients
including term neonates to visualize lesions with disrupted blood
brain barrier and/or abnormal vascularity in the brain (intracranial
lesions), spine and associated tissues.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="de46cce9-6cdf-439c-9040-a72c8e0aaa06"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 MRI of Extracranial/Extraspinal
Head and Neck</title>
                     <text>
                        <paragraph ID="p46428321389212461">ProHance is indicated for MRI in adults to visualize lesions in the
head and neck.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="e135aac8-49b5-8877-3555-070c6c612339"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240124"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l10373281407333577" styleCode="Disc">
                           <item>Recommended dose in adult and pediatric patients is 0.2
mL/kg (0.1 mmol/kg) body weight administered as rapid intravenous
infusion or bolus (<linkHtml href="#Section_2.1">2.1</linkHtml>)</item>
                           <item>Follow injection with a saline flush of at least 5 mL normal
saline (<linkHtml href="#Section_2.1">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="aa5cbde8-f784-46e7-b841-666a71a88e73"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dose</title>
                     <text>
                        <paragraph ID="p74577301610930561">The recommended dose for adult
and pediatric patients, including term neonates, is 0.2 mL/kg (0.1
mmol/kg) administered as a rapid intravenous infusion (10 mL/min to
60 mL/min) or bolus (greater than 60 mL/min). Table 1 provides weight-adjusted
recommended dose volumes.</paragraph>
                        <table ID="Table1RecommendedVolumeOfProHanceIn-8306A8B5" width="70%">
                           <colgroup>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Table 1: Recommended
Volume of ProHance Injection by Body Weight</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Body Weight (kg)</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Volume to be Administered
(mL)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">2.5</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">0.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">5</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">10</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">20</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">30</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">40</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">10</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">60</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">12</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">70</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">14</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">80</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">16</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">90</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">18</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">100</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">20</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">110</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">22</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">120</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">24</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">130</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">26</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">140</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">28</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">150</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">30</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="MRIOfTheCNSInAdults-8306C4FC">
                           <content styleCode="underline">MRI
of the CNS in Adults</content>:</paragraph>
                        <list listType="unordered" ID="ASupplementaryDoseOf0.4MLkg0.2Mmolk-8306C2EA" styleCode="Disc">
                           <item>A supplementary dose of 0.4 mL/kg (0.2 mmol/kg) may be given
up to 30 minutes after the first dose in adult patients with normal
renal function suspected of having poorly visualized CNS lesions,
in the presence of negative or equivocal scans</item>
                           <item>The safety and efficacy of supplementary dosing have not
been established in pediatric patients</item>
                        </list>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="1a0dd9d9-7b34-475c-b156-97943266060d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Administration</title>
                     <text>
                        <list listType="unordered" ID="VisuallyInspectProHanceForParticula-830AF63D" styleCode="Disc">
                           <item>Visually inspect ProHance for particulate matter and discoloration
prior to use</item>
                           <item>Do not administer the solution if it is discolored or particulate
matter is present</item>
                           <item>Concurrent medications or parenteral nutrition should not
be physically mixed with contrast agents and should not be administered
in the same intravenous line because of the potential for chemical
incompatibility</item>
                           <item>Inject at least a 5 mL normal saline flush immediately after
ProHance injection to ensure complete administration</item>
                           <item>Imaging procedures should be completed within 1 hour</item>
                           <item>ProHance vials are intended only for single-dose administration.
Administer immediately after opening and discard any unused product</item>
                        </list>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="7a296fde-629e-e184-a9a5-4950f1123cb7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Directions for Use </title>
                     <text>
                        <paragraph ID="Vials-830AF3EB">
                           <content styleCode="underline">Vials</content>
                        </paragraph>
                        <list listType="unordered" ID="l13318316261611120663" styleCode="Disc">
                           <item>Draw ProHance into the syringe immediately before use. Do
not pierce the rubber stopper more than once. Discard any unused vial
contents.</item>
                        </list>
                        <paragraph ID="ProHanceSingleDoseSyringe-830AF30C">
                           <content styleCode="underline">ProHance single dose syringe*</content>
                        </paragraph>
                        <list listType="unordered" ID="l13341316261611122585" styleCode="Disc">
                           <item>Screw the threaded tip of the plunger rod clockwise into
the cartridge plunger and push forward a few millimeters to break
any friction between the cartridge plunger and syringe barrel</item>
                        </list>
                        <list listType="unordered" ID="HoldingSyringeErectUnscrewThePlasti-830AEE75" styleCode="Disc">
                           <item>Holding syringe erect, unscrew the plastic tip cap from
the tip of the syringe and attach either a sterile, disposable needle
or tubing with a compatible Luer lock using a push-twist action (slip
tip)</item>
                           <item>Hold the syringe erect and push plunger forward until all
of the air is evacuated and fluid either appears at the tip of the
needle or the tubing is filled</item>
                           <item>Following the usual aspiration procedure, complete the injection</item>
                           <item>Inject at least a 5 mL normal saline flush immediately after
ProHance injection to ensure complete administration</item>
                           <item>Properly dispose of the syringe and any other materials
used</item>
                        </list>
                        <paragraph ID="TheSyringeAssemblyIsAHYPAKSCFSingle-830AECD5">*The syringe assembly is a HYPAK SCF® single dose syringe supplied
by Becton Dickinson</paragraph>
                     </text>
                     <effectiveTime value="20240124"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="2f153490-4b5e-42fa-adbf-ea1fa9a746d9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ProHanceIsSuppliedAsASterileNon-pyr-830AEBA3">ProHance
is supplied as a sterile, non-pyrogenic, and colorless to slightly
yellow solution available in single-dose vials or prefilled syringes.
Each mL contains 279.3 mg (0.5 mmol/mL) of gadoteridol for injection.</paragraph>
               </text>
               <effectiveTime value="20201228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="InjectionContains279.3MgmL0.5MmolmL-830AEAC6">Injection:
contains 279.3 mg/mL (0.5 mmol/mL) of gadoteridol supplied in single
dose vials or pre-filled syringes (<linkHtml href="#Section_2.3">2.3</linkHtml>, <linkHtml href="#Section_3">3</linkHtml>, <linkHtml href="#Section_16">16</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="8eb19133-87e0-1c5c-f098-0f949b2b44b4"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ProHanceIsContraindicatedInPatients-830AE9BD">ProHance is contraindicated
in patients with known allergic or hypersensitivity reactions to ProHance <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240124"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="AllergicOrHypersensitivityReactions-830AE8DA">Allergic
or hypersensitivity reactions to ProHance (<linkHtml href="#Section_4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="de95038a-14a5-d6e8-3574-24bb8aa875dc"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="L6" styleCode="Disc">
                           <item>Hypersensitivity: anaphylactic/anaphylactoid reactions with
cardiovascular, respiratory and cutaneous manifestations, ranging
from mild to severe reactions including shock can occur. Monitor patients
closely for need of emergency cardiorespiratory support (<linkHtml href="#Section_5.3">5.3</linkHtml>).</item>
                           <item>Gadolinium is retained for months or years in brain, bone,
and other organs. (<linkHtml href="#Section_5.4">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="2bc1b4a2-a461-06f6-8aeb-68e5683b6f42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk Associated with Intrathecal Use</title>
                     <text>
                        <paragraph ID="p1130443641705971953">Intrathecal administration of GBCAs can
cause serious adverse reactions including death, coma, encephalopathy,
and seizures. The safety and effectiveness of ProHance have not been
established with intrathecal use. ProHance is not approved for intrathecal
use <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="29562ead-e7af-93cb-c467-a728eaeb23cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Nephrogenic Systemic
Fibrosis</title>
                     <text>
                        <paragraph ID="Gadolinium-basedContrastAgentsGBCAs-830AE4CB">GCBAs increase the
risk for nephrogenic systemic fibrosis (NSF) among patients with impaired
elimination of the drugs. Avoid use of ProHance among these patients
unless the diagnostic information is essential and not available with
non-contrast MRI or other modalities. The GBCA-associated NSF risk
appears highest for patients with chronic, severe kidney disease (GFR
less than 30 mL/min/1.73m<sup>2</sup>) as well as
patients with acute kidney injury. The risk appears lower for patients
with chronic, moderate kidney disease (GFR 30- 59 mL/min/1.73m<sup>2</sup>) and little, if any, for patients with chronic, mild
kidney disease (GFR 60-89 mL/min/1.73m<sup>2</sup>). NSF may result in fatal or debilitating fibrosis affecting the
skin, muscle and internal organs. Report any diagnosis of NSF following
ProHance administration to Bracco Diagnostics (1-800-257-5181) or
FDA (1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>).</paragraph>
                        <paragraph ID="ScreenPatientsForAcuteKidneyInjuryA-830AE5D6">Screen patients
for acute kidney injury and other conditions that may reduce renal
function. Features of acute kidney injury consist of rapid (over hours
to days) and usually reversible decrease in kidney function, commonly
in the setting of surgery, severe infection, injury or drug-induced
kidney toxicity. Serum creatinine levels and estimated GFR may not
reliably assess renal function in the setting of acute kidney injury.
For patients at risk for chronically reduced renal function (for example,
age greater than 60 years, diabetes mellitus or chronic hypertension),
estimate the GFR through laboratory testing.</paragraph>
                        <paragraph ID="AmongTheFactorsThatMayIncreaseTheRi-830AE7AD">Among the factors
that may increase the risk for NSF are repeated or higher than recommended
doses of a GBCA and the degree of renal impairment at the time of
exposure. Record the specific GBCA and the dose administered to a
patient. For patients at highest risk for NSF, do not exceed the recommended
ProHance dose and allow a sufficient period of time for elimination
of the drug prior to re-administration. For patients receiving hemodialysis,
physicians may consider the prompt initiation of hemodialysis following
the administration of a GBCA in order to enhance the contrast agent’s
elimination. The usefulness of hemodialysis in the prevention of NSF
is unknown. <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12">12</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240826"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="48647632-8252-8502-0ff9-3220796acd43"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypersensitivity
Reactions</title>
                     <text>
                        <paragraph ID="p14370916261611123367">Anaphylactic and anaphylactoid reactions have been reported, involving
cardiovascular, respiratory, and/or cutaneous manifestations. Some
patients experienced circulatory collapse and died. In most cases,
initial symptoms occurred within minutes of ProHance administration
and resolved with prompt emergency treatment.</paragraph>
                        <paragraph ID="p14605116261611123376">Prior to ProHance administration, ensure
the availability of trained personnel and medications to treat hypersensitivity
reactions. Consider the risk for hypersensitivity reactions, especially
in patients with a history of hypersensitivity reactions or a history
of asthma or other allergic disorders. If such a reaction occurs,
stop ProHance and immediately begin appropriate therapy. Observe patients
for signs and symptoms of a hypersensitivity reaction during and for
up to 2 hours after ProHance administration.</paragraph>
                     </text>
                     <effectiveTime value="20240124"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="8fea6069-d4cc-1c25-29bb-2a491a16b63d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Gadolinium Retention</title>
                     <text>
                        <paragraph ID="p14608116261611123388">Gadolinium is retained for
months or years in several organs. The highest concentrations (nanomoles
per gram of tissue) have been identified in the bone, followed by
other organs (e.g. brain, skin, kidney, liver, and spleen). The duration
of retention also varies by tissue and is longest in bone. Linear
GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses,
retention varies among the linear agents with Omniscan (gadodiamide)
and Optimark (gadoversetamide) causing greater retention than other
linear agents [Eovist (gadoxetate disodium), Magnevist (gadopentetate
dimeglumine), MultiHance (gadobenate dimeglumine)]. Retention is lowest
and similar among the macrocyclic GBCAs [Dotarem (gadoterate meglumine),
Gadavist (gadobutrol), ProHance (gadoteridol)].</paragraph>
                        <paragraph ID="p14611116261611123397">Consequences of gadolinium retention in
the brain have not been established. Pathologic and clinical consequences
of GBCA administration and retention in skin and other organs have
been established in patients with impaired renal function <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>. There are rare reports of pathologic skin changes in
patients with normal renal function. Adverse events involving multiple
organ systems have been reported in patients with normal renal function
without an established causal link to gadolinium retention <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.2">6.2</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p14630116261611123444">While clinical
consequences of gadolinium retention have not been established in
patients with normal renal function, certain patients might be at
higher risk. These include patients requiring multiple lifetime doses,
pregnant and pediatric patients, and patients with inflammatory conditions.
Consider the retention characteristics of the agent when choosing
a GBCA for these patients. Minimize repetitive GBCA imaging studies,
particularly closely spaced studies when possible.</paragraph>
                     </text>
                     <effectiveTime value="20240124"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="ed002ac3-4a70-c6b5-d74d-713ee7324ea5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Acute Kidney Injury</title>
                     <text>
                        <paragraph ID="p14633116261611123455">In patients with chronically
reduced renal function, acute kidney injury requiring dialysis has
occurred with the use of GBCAs. The risk of acute kidney injury may
increase with increasing dose of the contrast agent; administer the
lowest dose necessary for adequate imaging.</paragraph>
                     </text>
                     <effectiveTime value="20240124"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="41294fdb-aa8d-b6b4-8c7f-7e101f6c8e3a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="TheFollowingSeriousAdverseReactions-830B6ABC">The following serious
adverse reactions are discussed in greater detail in other sections
of the prescribing information:</paragraph>
                  <list listType="unordered" ID="NephrogenicSystemicFibrosisseeBoxed-830B70AE" styleCode="Disc">
                     <item>Nephrogenic systemic fibrosis <content styleCode="italics">[see <linkHtml href="#Section_0">Boxed Warning</linkHtml> and Warnings and Precautions
(<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity reactions <content styleCode="italics">[see Contraindications
(<linkHtml href="#Section_4">4</linkHtml>) and Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="P43">The most commonly reported adverse reactions are
nausea and taste perversion with an incidence ≥ 0.9% (<linkHtml href="#Section_6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph ID="P20822168">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS,
Contact Bracco Diagnostics Inc. at 1-800-257-5181 or FDA at 1-800-FDA-1088
or <content styleCode="underline">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="89df3e67-25a0-aa54-c17b-8b6313cfd7fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="p59057321389216523">Because clinical trials are conducted
under widely varying conditions, adverse reaction rates observed in
the clinical trials of a drug cannot be directly compared to rates
in the clinical trials of another drug and may not reflect the rates
observed in practice.</paragraph>
                        <paragraph ID="p59198321389216540">The adverse events described in this section were observed in clinical
trials involving 3174 subjects (including 2896 adults and 278 pediatric
subjects ages 0 to 17 years) exposed to ProHance. Approximately 48%
of the subjects were men and ethnic distribution was 78% Caucasian,
6% Black, 3% Hispanic, 6% Asian, and 2% other. In 5% of the subjects,
race was not reported. Average age was 47 years (range from 1 day
to 91 years) and the exposure ranged from 0.03 to 0.3 mmol/kg.</paragraph>
                        <paragraph ID="p23094281407335459">Overall, approximately 5.8% of
subjects reported one or more adverse reactions during a follow-up
period that ranged from 24 hours to 7 days after ProHance administration.</paragraph>
                        <table ID="Table2ListsAdverseReactionsThatOccu-830BA97E" width="60%">
                           <caption>Table 2 lists adverse reactions that occurred in ≥ 0.4% subjects
who received ProHance.</caption>
                           <colgroup>
                              <col width="30%"/>
                              <col width="70%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
                                    <content styleCode="bold">Table 2: More frequent adverse reactions in clinical trials</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <content styleCode="bold">Reaction</content>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">
                                    <content styleCode="bold">Rate (%)<br/>N
= 3174</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Nausea</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">1.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dysgeusia</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.9%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">Headache</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.7%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Dizziness</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">0.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Urticaria</td>
                                 <td styleCode="Botrule Lrule Rrule Toprule">0.4%</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="TheFollowingAdditionalAdverseEvents-830BDCAB" width="100%">
                           <colgroup>
                              <col width="28*"/>
                              <col width="69*"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td colspan="2">The following additional adverse events occurred in
fewer than 0.4% of the subjects:</td>
                              </tr>
                              <tr>
                                 <td>General disorders and administration site conditions:</td>
                                 <td>Asthenia; chest discomfort, facial edema, feeling hot, injection
site coldness, injection site erythema, injection site pain, injection
site warmth, pain, pyrexia</td>
                              </tr>
                              <tr>
                                 <td>Cardiac:</td>
                                 <td>Angina pectoris, palpitations, atrio-ventricular block first degree</td>
                              </tr>
                              <tr>
                                 <td>Ear and labyrinth disorders:</td>
                                 <td>Ear discomfort, tinnitus</td>
                              </tr>
                              <tr>
                                 <td>Eye disorders:</td>
                                 <td>Eye pruritis, lacrimation increased</td>
                              </tr>
                              <tr>
                                 <td>Gastrointestinal disorders:</td>
                                 <td>Abdominal discomfort, abdominal pain, diarrhea, dry mouth, gingival
pain, oral pruritis, swollen tongue, vomiting</td>
                              </tr>
                              <tr>
                                 <td>Infections and infestations:</td>
                                 <td>Gingivitis, rhinitis</td>
                              </tr>
                              <tr>
                                 <td>Investigations:</td>
                                 <td>Alanine aminotransferase increased, aspartate aminotransferase
increased, blood chloride increased, blood pressure immeasurable,
blood urea decreased, hemoglobin decreased, heart rate increased</td>
                              </tr>
                              <tr>
                                 <td>Metabolism and nutrition disorders:</td>
                                 <td>Decreased appetite, hypoglycemia</td>
                              </tr>
                              <tr>
                                 <td>Musculoskeletal and connective tissue disorders:</td>
                                 <td>Back pain, musculoskeletal stiffness</td>
                              </tr>
                              <tr>
                                 <td>Nervous system disorders:</td>
                                 <td>Formication, hypoesthesia, hypokinesia, lethargy, loss of consciousness,
migraine, paresthesia, presyncope, seizure, syncope, taste disorder</td>
                              </tr>
                              <tr>
                                 <td>Psychiatric disorders:</td>
                                 <td>Anxiety, mental status changes</td>
                              </tr>
                              <tr>
                                 <td>Respiratory, thoracic and mediastinal disorders:</td>
                                 <td>Cough, dry throat, dyspnea, nasal discomfort, throat irritation</td>
                              </tr>
                              <tr>
                                 <td>Skin and subcutaneous tissue disorders:</td>
                                 <td>Hyperhidrosis, pruritis, rash, rash morbilliform</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule">Vascular disorders:</td>
                                 <td styleCode="Botrule">Flushing, hypotension, peripheral coldness,
vascular rupture, vasodilatation, vasospasm</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p460813641705969849"/>
                     </text>
                     <effectiveTime value="20240124"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="19ee9a71-225c-b35a-d5a0-236ecc4c9733"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="TheFollowingAdverseReactionsHaveBee-830CF63E">The
following adverse reactions have been identified during post approval
use of ProHance or other GBCAs that were not observed in the clinical
trials. Because these reactions are reported voluntarily from a population
of uncertain size, it is not always possible to reliably estimate
their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <table ID="CasesOfAcuteRenalFailureHaveBeenRep-830CF8B2" width="100%">
                           <colgroup>
                              <col width="30%"/>
                              <col width="70%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="2" valign="top">* Cases of acute renal failure have been
reported in patients with pre-existing severe renal impairment.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top">The following adverse drug reactions
have also been reported:</td>
                              </tr>
                              <tr>
                                 <td valign="top">General Disorders and Administration Site Conditions:</td>
                                 <td>Adverse events with variable onset and duration have been reported
after GBCA administration <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)].</content> These include fatigue, asthenia,
pain syndromes, and heterogeneous clusters of symptoms in the neurological,
cutaneous, and musculoskeletal systems.</td>
                              </tr>
                              <tr>
                                 <td valign="top">Cardiac disorders:</td>
                                 <td>Cardiac arrest, bradycardia, hypertension</td>
                              </tr>
                              <tr>
                                 <td valign="top">Gastrointestinal disorders:</td>
                                 <td>Acute pancreatitis with onset within 48 hours after GBCA administration</td>
                              </tr>
                              <tr>
                                 <td valign="top">Immune system disorders:</td>
                                 <td>Hypersensitivity/anaphylactoid reactions including cardiac arrest,
cyanosis, pharyngeal edema, laryngospasm, bronchospasm, angioedema,
cough, sneezing, conjunctivitis, eyelid edema, hyperhidrosis, urticaria <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>.</td>
                              </tr>
                              <tr>
                                 <td>Nervous system disorders:</td>
                                 <td>Coma, loss of consciousness, vasovagal reaction, tremor</td>
                              </tr>
                              <tr>
                                 <td>Respiratory, thoracic and mediastinal disorders:</td>
                                 <td>Respiratory arrest, acute respiratory distress syndrome, pulmonary
edema</td>
                              </tr>
                              <tr>
                                 <td>Renal and urinary system disorders:</td>
                                 <td>Acute renal failure *</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="0ac8de6b-0568-15ef-7af8-ac1cbde333bc"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240124"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p1258022611533671837">Pregnancy: Use only if imaging
is essential during pregnancy and cannot be delayed. (<linkHtml href="#Section_8.1">8.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="08e8f6a7-b0a0-4981-99f9-6d663cdf3d7d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="RiskSummaryGBCAsCrossThePlacentaAnd-830D61E1">
                           <content styleCode="underline">Risk
Summary</content>
                           <br/>GBCAs cross the placenta and result
in fetal exposure and gadolinium retention. The human data on the
association between GBCAs and adverse fetal outcomes are limited and
inconclusive (see Data). Because of the potential risks of gadolinium
to the fetus, use ProHance only if imaging is essential during pregnancy
and cannot be delayed.</paragraph>
                        <paragraph ID="InAnimalReproductionStudiesInRatsGa-830D749F">In animal reproduction
studies in rats, gadoteridol doubled the incidence of post-implantation
loss at up to 16 times the recommended human dose (RHD). There were
no adverse developmental effects observed in rabbits with intravenous
administration of gadoteridol during organogenesis at doses up to
19 times the recommended human dose of 0.1 mmol/kg <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph ID="TheEstimatedBackgroundRiskOfMajorBi-830D7336">The estimated background
risk of major birth defects and miscarriage for the indicated population
is unknown. All pregnancies have a background risk of birth defect,
loss, or other adverse outcomes. In the U.S. general population, the
estimated background risk of major birth defects and miscarriage in
clinically recognized pregnancies is 2 to 4% and is 15 to 20%, respectively.</paragraph>
                        <paragraph ID="DataHumanDataContrastAgentIsVisuali-830D864E">
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="italics">Human Data</content>
                           <br/>Contrast agent is visualized in the placenta and fetal tissues after
maternal GBCA administration. Cohort studies and case reports on exposure
to GBCAs during pregnancy have not reported a clear association between
GBCAs and adverse effects in the exposed neonates. However, a retrospective
cohort study, comparing pregnant women who had a GBCA MRI to pregnant
women who did not have an MRI, reported a higher occurrence of stillbirths
and neonatal deaths in the group receiving GBCA MRI. Limitations of
this study include a lack of comparison with non-contrast MRI and
lack of information about the maternal indication for MRI.</paragraph>
                        <paragraph ID="AnimalDataGadoliniumRetentionGBCAsA-830D84DD">
                           <content styleCode="italics">Animal Data</content>
                           <br/>Gadolinium Retention<br/>GBCAs
administered to pregnant non-human primates (0.1 mmol/kg on gestational
days 85 and 135) result in measurable gadolinium concentration in
the offspring in bone, brain, skin, liver, kidney, and spleen for
at least 7 months. GBCAs administered to pregnant mice (2 mmol/kg
daily on gestational days 16 through 19) result in measurable gadolinium
concentrations in the pups in bone, brain, kidney, liver, blood, muscle,
and spleen at one-month postnatal age.</paragraph>
                        <paragraph ID="ReproductiveToxicologyGadoteridolWa-830D8826">Reproductive Toxicology<br/>Gadoteridol was administered in intravenous doses of 0, 0.375, 1.5,
6.0, and 10 mmol/kg/day [0.6, 2.4, 9.7, and 16 times the recommended
human dose (RHD) based on body surface area (BSA)] to female rats
from gestational day (GD)6 until GD17. Gadoteridol at 10 mmol/kg/day
for 12 days during gestation doubled the incidence of post-implantation
loss. When rats were administered 6.0 or 10.0 mmol/kg/day for 12 days,
an increase in spontaneous locomotor activity was observed in the
offspring. Pregnant rabbits were administered gadoteridol in intravenous
doses of 0, 0.4, 1.5, and 6 mmol/kg/day (1.3, 4.8, and 19.4 times
the RHD based on BSA) from GD6 to GD18. Gadoteridol increased the
incidence of spontaneous abortion and early delivery in rabbits administered
6 mmol/kg/day for 13 days during gestation.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="f3c64616-8c58-4008-bfd7-ab09026b87ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="RiskSummaryThereAreNoDataOnThePrese-830F926A">
                           <content styleCode="underline">Risk Summary</content>
                           <br/>There are no data on the presence
of gadoteridol in human milk, the effects on the breastfed infant,
or the effects on milk production. However, published lactation data
on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium
dose is present in breast milk and there is limited GBCA gastrointestinal
absorption in the breast-fed infant. Gadoteridol is present in rat
milk (see Data). The developmental and health benefits of breastfeeding
should be considered along with the mother’s clinical need for ProHance
and any potential adverse effects on the breastfed infant from ProHance
or from the underlying maternal condition.</paragraph>
                        <paragraph ID="DataProHanceExcretionInTheMilkOfLac-830F91B5">
                           <content styleCode="underline">Data</content>
                           <br/>ProHance excretion in the milk of lactating rats was
evaluated at 30 minutes, 6 and 24 hours after intravenous administration
of 0.1 mmol/kg of <sup>153</sup>Gd-gadoteridol to
nursing mothers. Small amounts of compound were found in milk immediately
after injection (0.14% of the ID), with the amount declining to a
low level 24 hours after injection (&lt;0.01% of the ID).</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="dda43d82-baeb-46f6-b10e-d2b3539aadc2"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="TheSafetyAndEffectivenessOfProHance-830F903C">The safety and effectiveness
of ProHance have been established for use with MRI to visualize lesions
with abnormal blood brain barrier or abnormal vascularity of the brain,
spine, and associated tissues in pediatric patients from birth, including
term neonates, to 17 years of age. Pediatric use is based on evidence
of effectiveness in adults and in 103 pediatric patients 2 years of
age and older, in addition to experience in 125 pediatric patients
birth to less than 2 years of age that supported extrapolation from
adult data <content styleCode="italics">[see Clinical Studies (<linkHtml href="#Section_14">14</linkHtml>)]</content>. Adverse reactions in pediatric patients were
similar to those reported in adults <content styleCode="italics">[see Adverse Reactions
(<linkHtml href="#Section_6.1">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="TheSafetyAndEfficacyOf0.1MmolkgAndS-830F9495">The safety and efficacy
of &gt; 0.1 mmol/kg, and sequential and/or repeat procedures have not
been studied in pediatric patients <content styleCode="italics">[see Indications and Usage
(<linkHtml href="#Section_1">1</linkHtml>) and Dosage and Administration (<linkHtml href="#Section_2">2</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="NoCaseOfNSFAssociatedWithProHanceOr-830F9369">No case of NSF associated
with ProHance or any other GBCA has been identified in pediatric patients
ages 6 years and younger. Pharmacokinetic studies suggest that weight
normalized clearance of ProHance is similar in pediatric patients
and adults, including pediatric patients age younger than 2 years.
Normal estimated GFR (eGFR) is around 30 mL/min/1.73m<sup>2</sup> at birth and increases to mature levels around 1
year of age, reflecting growth in both glomerular function and relative
body surface area. Clinical studies in pediatric patients younger
than 1 year of age have been conducted in patients with the following
minimum eGRF; 59.37 mL/min/1.73m<sup>2</sup> (age
just after birth to &lt; 30 days), 118.84 mL/min/1.73m<sup>2</sup> (age 30 days to &lt; 6 months), 140.44 mL/min/1.73m<sup>2</sup> (age 6 to 12 months).</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="s36044281407336136">
                     <id root="990d35d0-0018-4c89-b989-611e531ee855"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="OfTheTotalNumberOf2673AdultSubjects-830F95AB">Of the total number
of 2673 adult subjects in clinical studies of ProHance, 22% were 65
and over. No overall differences in safety were observed between these
elderly subjects and the younger subjects.</paragraph>
                        <paragraph ID="ProHanceIsKnownToBeSubstantiallyExc-830F96F3">ProHance is known
to be substantially excreted by the kidneys, and the risk of toxic
reactions from ProHance may be greater in patients with impaired renal
function. Because elderly patients are more likely to have decreased
renal function, it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="a4d40dcc-ec3f-f857-1716-eeddb2dcf90c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="NoProHanceDosageAdjustmentIsRecomme-830F97CF">No ProHance
dosage adjustment is recommended for patients with renal impairment.
Gadoteridol can be removed from the body by hemodialysis <content styleCode="italics">[see
Warning and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>) and
Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240124"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="086e266f-40c3-40e0-88b9-5cc72b143640"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10  OVERDOSAGE</title>
               <text>
                  <paragraph ID="ClinicalConsequencesOfOverdoseWithP-830F9949">Clinical consequences
of overdose with ProHance have not been reported. The safety of ProHance
has been tested in clinical studies using doses up to 0.3 mmol/kg
and no clinical consequences related to increasing dose have been
observed to date. ProHance can be removed by hemodialysis <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.6">8.6</linkHtml>) and Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20201228"/>
            </section>
         </component>
         <component>
            <section ID="GN65929">
               <id root="9f60cea9-e9b9-40a3-86ed-f7c7a3fc0e9a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph ID="ProHanceAGadolinium-basedParamagnet-834147C8">ProHance,
a gadolinium-based paramagnetic MRI contrast agent, is a colorless
to slightly yellow aqueous, sterile, nonpyrogenic injectable solution.
Each mL contains 279.3 mg (0.5 mmol/mL) gadoteridol, 0.23 mg calteridol
calcium, 1.21 mg tromethamine and water for injection; pH adjusted
with hydrochloric acid and/or sodium hydroxide. ProHance contains
no antimicrobial preservative.</paragraph>
                  <paragraph ID="GadoteridolIsTheGadoliniumComplexOf-83414897">Gadoteridol is the
gadolinium complex of 10-(2-hydroxy-propyl)-1,4,7,10- tetraazacyclododecane-1,4,7-triacetic
acid with a molecular weight of 558.7, an empirical formula of C<sub>17</sub>H<sub>29</sub>N<sub>4</sub>O<sub>7</sub>Gd and has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ProHanceHasAPHOf6.5To8.0.PertinentP-83415A35">ProHance has a pH
of 6.5 to 8.0. Pertinent physiochemical parameters are provided below:</paragraph>
                  <table ID="Osmolality630MOsmolkgWaterAt37CVisc-8341586B" width="50%">
                     <colgroup>
                        <col width="35%"/>
                        <col width="65%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">Osmolality</td>
                           <td styleCode="Botrule Lrule Rrule Toprule">630 mOsmol/kg water at 37 °C</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">Viscosity</td>
                           <td styleCode="Botrule Lrule Rrule Toprule">1.3 cP at 37 °C</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">Density</td>
                           <td styleCode="Botrule Lrule Rrule Toprule">1.137 g/mL at 25 °C</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ProHanceHasAnOsmolalityThatIs2.2Tim-83415729">ProHance has an osmolality that is 2.2 times that of plasma (285
mOsmol/kg water) and is hypertonic under conditions of use.</paragraph>
               </text>
               <effectiveTime value="20220601"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Prohance Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ph-struct.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="47e2aa05-3519-fc31-30ab-f56b9d2e0d72"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240124"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="db7bc812-cd83-44ac-a8ec-962f0181f8d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="GadoteridolIsAParamagneticAgentAndA-8341B507">Gadoteridol
is a paramagnetic agent and, as such, develops a magnetic moment when
placed in a magnetic field. The relatively large magnetic moment produced
by the paramagnetic agent results in a relatively large local magnetic
field, which can enhance the relaxation rates of water protons in
the vicinity of the paramagnetic agent.</paragraph>
                        <paragraph ID="InMRIVisualizationOfNormalAndPathol-8341B5C7">In MRI, visualization
of normal and pathologic brain tissue depends, in part, on variations
in the radiofrequency signal intensity that occur with: 1) differences
in proton density; 2) differences of the spin-lattice or longitudinal
relaxation times (T1); and 3) differences in the spin-spin or transverse
relaxation time (T2). When placed in a magnetic field, gadoteridol
decreases T1 relaxation times in the target tissues. At recommended
doses, the effect is observed with greatest sensitivity in the T1-weighted
sequences.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="GN66143">
                     <id root="d441e68c-17a7-43d5-ae2c-f018362a265e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="GadoteridolAffectsProtonRelaxationT-8341B6B1">Gadoteridol
affects proton relaxation times and consequently the MR signal. Signal
intensity is affected by the dose and relaxivity of the gadoteridol
molecule. Consistently, for all gadolinium based contrast agents,
the relaxivity of gadoteridol decreases with the increase of the magnetic
field strength used in clinical MRI (0.2 – 3.0T).</paragraph>
                        <paragraph ID="DisruptionOfTheBlood-brainBarrierOr-8341B780">Disruption of the
blood-brain barrier or abnormal vascularity allows accumulation of
gadoteridol in lesions such as neoplasms, abscesses, and subacute
infarcts. The pharmacokinetics of gadoteridol in various lesions is
not known.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Pharm">
                     <id root="5db54c18-df51-4385-270f-1a47bd3d0a10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ThePharmacokineticsOfIntravenouslyA-8341B922">The
pharmacokinetics of intravenously administered gadoteridol in normal
subjects conforms to a two-compartment open model.</paragraph>
                        <paragraph ID="Distribution-8341BA29">
                           <content styleCode="underline">Distribution</content>
                           <br/>After intravenous administration, gadoteridol is rapidly distributed
in the extracellular space. The plasma distribution volume (mean ±
SD) for the non-renally impaired adults was 0.205 ± 0.025 L/kg. It
is unknown if protein binding of gadoteridol occurs <content styleCode="italics">in vivo</content>.</paragraph>
                        <paragraph ID="FollowingGBCAAdministrationGadolini-8341CFFE">Following GBCA administration,
gadolinium is present for months or years in brain, bone, skin, and
other organs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p1036316261611159198">
                           <content styleCode="underline">Metabolism</content>
                           <br/>It is unknown if biotransformation or decomposition of gadoteridol
occur in vivo.</paragraph>
                        <paragraph ID="p18215516261611159211">
                           <content styleCode="underline">Elimination</content>
                           <br/>Gadoteridol is eliminated unchanged
via the kidneys. The elimination half-life (mean ± SD) is about 1.57
± 0.08 hours. Within 24 hours post-injection, 94.4 ± 4.8% of the dose
is excreted in the urine. The renal and plasma clearance rates (1.41
± 0.33 mL/ min/kg and 1.50 ± 0.35 mL/ min/kg, respectively) of gadoteridol
are essentially identical, indicating no alteration in elimination
kinetics on passage through the kidneys and that the drug is essentially
cleared through the kidney. The volume of distribution (204 ± 58 mL/kg)
is equal to that of extracellular water, and clearance is similar
to that of substances which are subject to glomerular filtration.</paragraph>
                        <paragraph ID="p668513641705969849"/>
                        <paragraph ID="p668713641705969849">
                           <content styleCode="underline">Specific Populations</content>
                           <br/>
                           <content styleCode="italics">Gender</content>
                           <br/>Gender has no clinically
relevant effect on the pharmacokinetics of gadoteridol.</paragraph>
                        <paragraph ID="p669813641705969849">
                           <content styleCode="italics">Geriatric</content>
                           <br/>There were 7 elderly subjects receiving 0.1 (n = 3) and 0.3 mmol/kg
(n = 4) dose of ProHance. The clearance was slightly lower in elderly
subjects as compared to non-elderly subjects <content styleCode="italics">[see Use in Specific
Populations (<linkHtml href="#s36044281407336136">8.5</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p691913641705969849">
                           <content styleCode="italics">Pediatric</content>
                           <br/>A population pharmacokinetic analysis incorporated data
from 79 subjects, 45 males and 34 females. Among 79 subjects, 41 were
healthy subjects including 28 pediatric subjects between 5 years and
15 years of age. The pediatric subjects received a single intravenous
dose of 0.1 mmol/kg of ProHance. From population PK model, the mean
C<sub>max</sub> was 0.66 ± 0.21 mmol/L in pediatric subjects
2 years to 6 years of age, 0.58 ± 0.06 mmol/L in pediatric subjects
6 years to 12 years of age, and 0.68 ± 0.12 mmol/L in adolescent subjects
older than 12 years. The mean AUC<sub>0-∞</sub> was 0.74
± 0.20 mmol/L⋅h in pediatric subjects 2 years to 6 years of age, 0.74
± 0.09 mmol/L⋅h in pediatric subjects 6 years to 12 years of age,
and 0.98 ± 0.09 mmol/L⋅h in adolescent subjects older than 12 years
of age. The mean distribution half-life (t<sub>1/2,alpha</sub>) was 0.14 ± 0.04 hours in pediatric subjects 2 years to 6 years
of age, 0.18 ± 0.07 hours in pediatric subjects 6 years to 12 years
of age, and 0.20 ± 0.07 hours in adolescent subjects older than 12
years of age. The mean elimination half-life (t<sub>1/2,beta</sub>) was 1.32 ± 0.006 hours in pediatric subjects 2 years to 6 years,
1.32 ± 0.07 hours in pediatric subjects 6 years to 12 years of age,
and 1.61 ± 0.19 hours in adolescent subjects older than 12 years of
age. There was no significant gender-related difference in the pharmacokinetic
parameters in the pediatric patients. Over 80% of the dose was recovered
in urine for pediatric subjects after 10 hours. Pharmacokinetic simulations
indicate similar half-life, AUC, and C<sub>max</sub> values
for ProHance in pediatric subjects less than 2 years of age when compared
to those reported for adults; no age-based dose adjustment is necessary
for this pediatric population.</paragraph>
                        <paragraph ID="p694613641705969849">
                           <content styleCode="italics">Renal Impairment</content>
                           <br/>In patients with impaired renal function, the serum half-life of
gadoteridol is prolonged. After intravenous injection of 0.1 mmol/kg,
the elimination half-life of gadoteridol was 10.65 ± 0.06 hours in
mild to moderately impaired patients (creatinine clearance 30 to 60
mL/min) and 9.10±0.26 hours in severely impaired patients not on dialysis
(creatinine clearance 10 to 30 mL/min). The mean serum clearance of
gadoteridol in patients with normal renal function was 116.14 ± 26.77
mL/min, compared to 37.2 ± 16.4 mL/min in patients with mild to moderate
renal impairment and 16.0 ± 3.0 mL/min in patients with severe renal
impairment.</paragraph>
                        <paragraph ID="p695413641705969849">In patients
with moderately and severely impaired renal function about 97% and
76% of the administered dose was recovered in the urine within 7 days
and 14 days, respectively.</paragraph>
                        <paragraph ID="p695713641705969849">For patients receiving hemodialysis, physicians
may consider the prompt initiation of hemodialysis following the administration
of ProHance in order to enhance the contrast agent’s elimination.
Seventy- two percent (72%) of gadoteridol is removed from the body
after the first dialysis, 91% after the second dialysis, and 98% after
the third dialysis session. <content styleCode="italics">[See Warnings and Precautions
(<linkHtml href="#Section_5.2">5.2</linkHtml>) and Use in Specific Populations
(<linkHtml href="#Section_8.6">8.6</linkHtml>).]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240124"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="d3a162ea-4cf3-4901-b55b-bbe80e92b9b6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20201228"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="08c12299-56c9-4f7f-a03c-9371a49e9052"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="P30">No animal studies have been performed to evaluate
the carcinogenic potential of gadoteridol.</paragraph>
                        <paragraph ID="p1078813301611021512">No changes in reproductive performance and
outcome of pregnancy were caused in rats and rabbits by daily intravenous
administration of ProHance to parent animals before and during gestation
up to 1.5 mmol/kg/day (15 times the recommended human dose).</paragraph>
                        <paragraph ID="p35986321389218031">Gadoteridol did not demonstrate
genotoxic activity in: bacterial reverse mutation assays using <content styleCode="italics">Salmonella typhimurium</content> and <content styleCode="italics">Escherichia coli</content>; a mouse lymphoma forward mutation assay; an <content styleCode="italics">in vitro</content> cytogenetic assay measuring chromosomal aberration frequencies in
Chinese hamster ovary cells; and an <content styleCode="italics">in vivo</content> mouse
micronucleus assay at intravenous doses up to 5.0 mmol/kg.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="ddd78512-8a20-4578-8e00-feb061376121"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <effectiveTime value="20201229"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="d799813e-784d-4a12-bc02-525fc57ca0c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 MRI of the CNS</title>
                     <text>
                        <paragraph ID="ProHanceWasEvaluatedInTwoMulticente-83484BBC">ProHance
was evaluated in two multicenter trials of 310 evaluable patients
suspected of having neurological pathology. After the administration
of ProHance 0.1 mmol/kg IV, the results were similar to those described
below <content styleCode="italics">[see Clinical Studies (<linkHtml href="#Section_14.2">14.2</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="InAnotherMulticenterStudyOf49Evalua-83484C84">In another multicenter
study of 49 evaluable adult patients with known intracranial tumor
with high suspicion of having cerebral metastases, two doses of ProHance
were administered. First ProHance 0.1 mmol/kg was injected followed
30 minutes later with 0.2 mmol/kg. In comparison to the 0.1 mmol/kg
dose alone, the addition of the 0.2 mmol/kg dose improved visualization
in 67% and improved border definition in 56% of patients. In comparison
to non-contrast MRI, the number of lesions after 0.1 mmol/kg increased
in 34% of patients. After ProHance 0.2 mmol/kg, this increased to
44%.</paragraph>
                        <paragraph ID="PediatricPatientsProHanceWasEvaluat-83484D71">
                           <content styleCode="underline">Pediatric
Patients</content>
                           <br/>ProHance was evaluated in a multicenter
study of 103 patients undergoing brain or spine MRI. Among these patients,
the age range was 2 to 20 years; 54 were between 2 and 12 years of
age; 74% were Caucasian, 11% Black, 12% Hispanic, 2% Asian, and 2%
other. ProHance was given in one single 0.1 mmol/kg dose. Repeat dosing
was not studied. The results of the non-contrast and ProHance MRI
scans were compared. In this database, MRI enhancement was noted in
approximately 60% of the scans and additional diagnostic information
in 30 to 95% of the scans.</paragraph>
                        <paragraph ID="AProspectivelyPlannedStudyOf125Pedi-83484E36">A prospectively
planned study of 125 pediatric patients younger than 2 years of age
retrospectively selected was performed. These patients (70 boys and
55 girls) had an age range of 1 day to 24 months old; 17 were less
than 1 month of age, 40 were between 1 month and 6 months of age,
29 were between 6 months and 12 months of age, and 39 were between
12 months and 24 months of age; 56% were Caucasian, 25% Black, 5%
Asian, and 14% other. ProHance was given in one single 0.1 mmol/kg
dose. Repeat dosing was not studied. Three independent, blinded readers
evaluated pre-contrast MRI image sets and paired pre-plus-post-contrast
MRI image sets using ProHance and rated the images according to three
co-primary visualization endpoints: lesion border delineation, visualization
of lesion internal morphology, and lesion contrast enhancement. All
three blinded readers reported improvement in the paired image sets
for each of the three co-primary endpoints.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="9afd65b4-d135-407f-b2f9-660f0ff9f230"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 MRI of the Head
and Neck</title>
                     <text>
                        <paragraph ID="ProHanceWasEvaluatedInTwoBlindedRea-83484F60">ProHance was evaluated
in two blinded read studies in a total of 133 adults who had an indication
for head and neck extracranial or extraspinal MRI. These 133 adults
(74 men, 59 women) had a mean age of 53 with a range of 19 to 76 years.
Of these patients, 85% were Caucasian, 13% Black, 2% Asian, and less
than 1% other. The results of the non-contrast and contrast MRI scans
were compared. Approximately 75-82% of the scans were enhanced, 45-48%
of the scans provided additional diagnostic information, and 8-25%
of the diagnoses were changed. The relevance of the findings to disease
sensitivity and specificity has not been fully evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20201228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="32cbaaa2-76ec-4aab-ad5d-fbf2a84a73a9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE
AND HANDLING</title>
               <text>
                  <paragraph ID="HowSuppliedProHanceIsSuppliedAsASte-8348506C">
                     <content styleCode="underline">How Supplied</content>
                     <br/>ProHance is supplied as a sterile, nonpyrogenic, and
colorless to slightly yellow solution containing 279.3 mg/mL (0.5
mmol/mL) of gadoteridol in single-dose rubber stoppered vials or prefilled
syringes; ProHance is available in boxes of:</paragraph>
                  <paragraph ID="Five5MLFillsInSingleDose15MLVialsND-834851CE">Five 5 mL fills
in single dose 15 mL vials (NDC 0270-1111-04)<br/>Five 10 mL
fills in single dose 30 mL vials (NDC 0270-1111-01)<br/>Five
15 mL fills in single dose 30 mL vials (NDC 0270-1111-02)<br/>Five 20 mL fills in single dose 30 mL vials (NDC 0270-1111-03)</paragraph>
                  <paragraph ID="StorageAndHandlingStoreAt25C77F.Exc-83485302">
                     <content styleCode="underline">Storage and Handling</content>
                     <br/>Store at 25°C (77° F).
Excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled
Room Temperature]. Protect from light. DO NOT FREEZE. Should freezing
occur in the vial, ProHance should be brought to room temperature
before use. If allowed to stand at room temperature for a minimum
of 60 minutes, ProHance should return to a clear, colorless to slightly
yellow solution. Before use, examine the product to assure that all
solids are redissolved and that the container and closure have not
been damaged. Should solids persist, discard vial.</paragraph>
               </text>
               <effectiveTime value="20201229"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="064e7ea9-9b16-bf16-d589-6eb09b38f1e8"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="MedicationGuide-83485387">
                     <content styleCode="underline">Medication Guide</content>
                  </paragraph>
                  <list listType="unordered" ID="l1256179961525626447" styleCode="Disc">
                     <item>Advise the patient to read the FDA-approved patient labeling
(<linkHtml href="#s10753536511516034985">Medication Guide</linkHtml>) found
at <content styleCode="underline">www.prohancemedicationguide.com</content>.</item>
                  </list>
                  <paragraph ID="NephrogenicSystemicFibrosisInstruct-83485557">
                     <content styleCode="underline">Nephrogenic Systemic Fibrosis</content>
                     <br/>Instruct
patients to inform their physician if they:</paragraph>
                  <list listType="unordered" ID="l41123281407337210" styleCode="Disc">
                     <item> have a history of kidney disease</item>
                     <item> have recently received a GBCA</item>
                  </list>
                  <paragraph ID="GBCAsIncreaseTheRiskForNSFInPatient-834855E1">GBCAs increase the risk for NSF in patients with impaired elimination
of the drugs. To counsel patients at risk for NSF:</paragraph>
                  <list listType="unordered" ID="l87127281407337251" styleCode="Disc">
                     <item> describe the clinical manifestations of NSF</item>
                     <item> describe procedures to screen for the detection of renal
impairment</item>
                  </list>
                  <paragraph ID="InstructPatientsToContactTheirPhysi-834857B5">Instruct patients to contact their physician if they develop signs
or symptoms of NSF following ProHance administration, such as burning,
itching, swelling, scaling, hardening and tightening of the skin;
red or dark patches on the skin; stiffness in joints with trouble
moving, bending or straightening the arms, hands, legs or feet; pain
in the hip bones or ribs; or muscle weakness.</paragraph>
                  <paragraph ID="GeneralPrecautions-83485871">
                     <content styleCode="underline">General Precautions</content>
                  </paragraph>
                  <list listType="unordered" ID="l1485011301611024794" styleCode="Disc">
                     <item>Pregnancy: Advise a pregnant woman of the potential risk
of fetal exposure to ProHance <content styleCode="italics">[see Use in Specific Populations
(<linkHtml href="#Section_8.1">8.1</linkHtml>)]</content>
                     </item>
                     <item>Gadolinium retention: Advise patients that gadolinium is
retained for months or years in brain, bone, skin, and other organs
in patients with normal renal function. The clinical consequences
of retention are unknown. Retention depends on multiple factors and
is greater following administration of linear GBCAs than following
administration of macrocyclic GBCAs <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph ID="ManufacturedForBraccoDiagnosticsInc-834858CD">
                     <br/>Manufactured for:<br/>Bracco Diagnostics Inc.<br/>Princeton, NJ 08540</paragraph>
                  <paragraph ID="ByBIPSOGmbH78224SingenGermany-83485A39">By BIPSO GmbH<br/>78224 Singen (Germany)</paragraph>
                  <paragraph ID="December2020-83485AFF">March 2025</paragraph>
                  <paragraph ID="CL6FF05-83485BD1">CL101A-06</paragraph>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="s10753536511516034985">
               <id root="3acfb93e-ef9e-bca5-fcb4-604604118ab5"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table ID="Table_MedGuide" border="0" width="100%">
                     <colgroup>
                        <col span="2"/>
                     </colgroup>
                     <tfoot>
                        <tr>
                           <td valign="top">This Medication Guide has been approved by the U.S.
Food and Drug Administration</td>
                           <td align="right" valign="top">Revised: 03/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2" align="center">
                              <content styleCode="bold">MEDICATION GUIDE<br/>PROHANCE<sup>®</sup>
                                 <content styleCode="italics">(prō-ˈhan(t)s)</content>
                                 <br/>(Gadoteridol injection)<br/>for intravenous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What is the
most important information I should know about PROHANCE?</content>
                              <list listType="unordered" ID="l12074105971525320125" styleCode="Disc">
                                 <item>GBCAs like PROHANCE may cause serious side effects including
death, coma, encephalopathy, and seizures when it is given intrathecally
(injection given into the spinal canal). It is not known if PROHANCE
is safe and effective with intrathecal use. PROHANCE is not approved
for this use.</item>
                                 <item>PROHANCE contains a metal called gadolinium. Small amounts
of gadolinium can stay in your body including the brain, bones, skin
and other parts of your body for a long time (several months to years).</item>
                                 <item>It is not known how gadolinium may affect you, but so far,
studies have not found harmful effects in patients with normal kidneys.</item>
                                 <item>Rarely, patients have reported pains, tiredness, and skin,
muscle or bone ailments for a long time, but these symptoms have not
been directly linked to gadolinium.</item>
                                 <item>There are different GBCAs that can be used for your MRI
exam. The amount of gadolinium that stays in the body is different
for different gadolinium medicines. Gadolinium stays in the body more
after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance.
Gadolinium stays in the body the least after Dotarem, Gadavist, or
ProHance.</item>
                                 <item>People who get many doses of gadolinium medicines, women
who are pregnant and young children may be at increased risk from
gadolinium staying in the body.</item>
                                 <item>Some people with kidney problems who get gadolinium medicines
can develop a condition with severe thickening of the skin, muscles
and other organs in the body (nephrogenic systemic fibrosis). Your
healthcare provider should screen you to see how well your kidneys
are working before you receive PROHANCE.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What is PROHANCE?</content>
                              <list listType="unordered" ID="l9990421141517603564" styleCode="Disc">
                                 <item>PROHANCE is a prescription medicine called a gadolinium-based
contrast agent (GBCA). PROHANCE, like other GBCAs, is used with a
magnetic resonance imaging (MRI) scanner.</item>
                                 <item>An MRI exam with a GBCA, including PROHANCE, helps your
doctor to see problems better than an MRI exam without a GBCA.</item>
                                 <item>Your doctor has reviewed your medical records and has determined
that you would benefit from using a GBCA with your MRI exam.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">Do not receive
PROHANCE if you</content> have had a severe allergic reaction to PROHANCE.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">Before receiving
PROHANCE, tell your healthcare provider about all your medical conditions,
including if you</content>:<list listType="unordered" ID="l10534721141517603733" styleCode="Disc">
                                 <item>have had any MRI procedures in the past where you received
a GBCA. Your healthcare provider may ask you for more information
including the dates of these MRI procedures.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known
if PROHANCE can harm your unborn baby. Talk to your healthcare provider
about the possible risks to an unborn baby if a GBCA such as PROHANCE
is received during pregnancy</item>
                                 <item>have kidney problems, diabetes, or high blood pressure</item>
                                 <item>have had an allergic reaction to dyes (contrast agents)
including GBCAs</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What are
the possible side effects of PROHANCE?</content>
                              <list listType="unordered" ID="l10790721141517603847" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">See “What is the most important information I should
know about PROHANCE?”</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Allergic reactions. PROHANCE can cause allergic reactions
that can sometimes be serious. Your healthcare provider will monitor
you closely for symptoms of an allergic reaction.</content>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of PROHANCE include: nausea,
distortion of the sense of taste, and headache.</content>
                              <br/>These
are not all the possible side effects of PROHANCE.<br/>Call
your doctor for medical advice about side effects. You may report
side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">General information
about the safe and effective use of PROHANCE.</content>
                              <br/>Medicines
are sometimes prescribed for purposes other than those listed in a
Medication Guide. You can ask your healthcare provider for information
about PROHANCE that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What are
the ingredients in PROHANCE?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:
gadoteridol</content>
                              <br/>
                              <content styleCode="bold">Inactive ingredients: calteridol
calcium, tromethamine</content>
                              <br/>Manufactured by: BIPSO GmbH-78224
Singen (Germany)<br/>Manufactured for: Bracco Diagnostics Inc.,
Princeton, NJ 08540 <br/>For more information, go to www.imaging.bracco.com
or call 1-800-257-5181.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="Section_P1">
               <id root="ad7c7df6-2bb4-4d88-9bfa-e0db8c803e90"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p21281419224824"/>
                  <paragraph ID="p51281419224824">Prohance 5mL Vial label<br/> NDC 0270-1111-04</paragraph>
                  <renderMultiMedia referencedObject="g284281419224946"/>
               </text>
               <effectiveTime value="20201228"/>
               <component>
                  <observationMedia ID="g284281419224946">
                     <text>5 mL Vial</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="prohance-5-ml-vial.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_P4">
               <id root="d1965707-f611-33f0-6a90-107eff6a116e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p21281419224996">Prohance
5x10 mL Box<br/>NDC: 0270–1111–01</paragraph>
                  <renderMultiMedia referencedObject="g254301732645488"/>
               </text>
               <effectiveTime value="20241202"/>
               <component>
                  <observationMedia ID="g254301732645488">
                     <text>prohance-box-5x10-ml</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="prohance-box-5x10-ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>